By Cecilia Butini

 

The European Commission said Wednesday that it has signed a contract with GlaxoSmithKline PLC for the supply of a monoclonal antibody that can be used for the treatment of Covid-19.

The Commission said the contract is a procurement framework contract for sotrovimab, a drug developed by GlaxoSmithKline in collaboration with VIR Biotechnology Inc.

The treatment is part of a portfolio of five promising therapeutics which the Commission singled out in June as part of its Covid-19 therapeutics strategy, and is currently under rolling review by the European Medicines Agency.

"Sotrovimab can be used for the treatment of coronavirus patients with mild symptoms who do not require supplemental oxygen, but who are at high risk for severe COVID-19," according to the Commission.

According to the agreement with GlaxoSmithKline, member states can purchase the drug once it has received either emergency authorization in the state, or a marketing authorization from the EU Medicines Agency.

 

Write to Cecilia Butini at cecilia.butini@wsj.com

 

(END) Dow Jones Newswires

July 28, 2021 06:49 ET (10:49 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Glaxosmithkline (LSE:GSK)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Glaxosmithkline Charts.
Glaxosmithkline (LSE:GSK)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Glaxosmithkline Charts.